EverspanRapamycin (Sirolimus)
An mTOR inhibitor showing lifespan extension in animal models, now under investigation for human aging.
Human Trials
15
2,500 participants
Risk Level
Monthly Cost
Requires prescription. Cost varies by source – compounding pharmacies vs. retail.
Quick Facts
- Category
- Pharmaceutical
- Research Field
- Pharmacology
- Evidence Grade
- B- – Promising
- Risk Level
- Medium
- Monthly Cost
- $50 – $200
- Human Trials
- 15
Typical Dose
2–6 mg once weekly (longevity biohacking protocol)
Range
1–10 mg/week
For informational purposes only – not medical advice. See disclaimer
Research Velocity
Mechanism of Action
Rapamycin inhibits the mechanistic target of rapamycin (mTOR) complex 1, a central regulator of cell growth and metabolism. By suppressing mTOR signaling, rapamycin activates autophagy (cellular cleanup), reduces senescent cell accumulation, improves immune function at low doses, and shifts cellular metabolism toward maintenance and repair rather than growth. In animal models, these effects consistently extend lifespan across multiple species.
Overview
Rapamycin (sirolimus) is arguably the most promising pharmacological longevity intervention currently under investigation. Originally discovered in a soil sample from Easter Island (Rapa Nui), it was first developed as an immunosuppressant for organ transplant patients. Its longevity potential was revealed when the NIA's Interventions Testing Program showed it extended lifespan in mice even when started late in life.
The drug works by inhibiting mTOR (mechanistic target of rapamycin), a master regulator of cell growth. When mTOR is suppressed, cells shift from growth mode to maintenance mode – activating autophagy, reducing inflammation, and clearing damaged cellular components. This mechanism makes rapamycin one of the few interventions that directly targets a recognized hallmark of aging.
Human evidence is still limited but growing rapidly. The key insight from early human studies is that dosing matters enormously – the intermittent, low-dose protocols used in longevity contexts (typically 3-6mg once weekly) appear to have a very different risk profile than the daily high-dose regimens used in transplant medicine. Multiple clinical trials are currently underway to evaluate rapamycin specifically for aging-related endpoints.
Known Interactions
- Immunosuppressive at high doses – longevity dosing uses lower, intermittent protocols (e.g., weekly rather than daily).
- Grapefruit juice increases bioavailability significantly – some protocols use this intentionally.
- May interact with other mTOR-affecting compounds (e.g., metformin also affects mTOR pathway).
Legal Status by Country
Your country (United States)
FDA-approved for transplant rejection; off-label use for aging requires prescription
📍 = your selected country · ✈️ = medical tourism destination · Always verify current local regulations before travel.
Key Research
- 2009
First landmark study showing rapamycin extends lifespan in mammals (ITP)
- 2014
Novartis trial showing low-dose mTOR inhibition enhanced immune response in elderly humans
- 2019
Expert review of rapamycin's longevity potential and clinical considerations
Related Interventions
17-alpha-Estradiol
Research suggests this estrogen stereoisomer may extend lifespan in male mice while avoiding feminizing effects.
Acarbose
An alpha-glucosidase inhibitor showing potential longevity benefits through metabolic modulation and caloric restriction mimetics.
Low-Dose Aspirin
Well-studied anti-platelet therapy with extensive evidence for cardiovascular protection and potential longevity benefits.
BPC-157
Synthetic peptide derived from gastric juice showing promise for tissue repair and wound healing in animal studies.
Last verified: 2026-03-14